PMID- 8690751
OWN - NLM
STAT- MEDLINE
DCOM- 19960823
LR  - 20200304
IS  - 0171-5216 (Print)
IS  - 0171-5216 (Linking)
VI  - 122
IP  - 7
DP  - 1996
TI  - Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells.
PG  - 409-15
AB  - Susceptibility of lymphoma cells (Daudi, HD-Mar) to Newcastle disease virus 
      toxicity was found to be higher than that of lymphoblastoid cells (Milstein) and 
      of resting peripheral blood lymphocyte (PBL). Phytohemagglutinin- and/or 
      pokeweed-mitogen-activated PBL however, exhibited, elevated sensitivity, similar 
      to that of lymphoma cells. The level of cytotoxicity was monitored by cell 
      viability, inhibition of DNA synthesis and release of 51Cr. When Daudi cells were 
      mixed with PBL they were significantly more sensitive to the killing effect of 
      the virus (70% mortality compared to 30% 30 h after infection, P < 0.05). The 
      degree of sensitivity to viral cytotoxicity was unrelated to the efficacy of 
      adsorption, which was similar for all cell lines as shown by immunofluorescent 
      staining and flow cytometry. Also an influenza strain A/PR/8/34 (H1N1) adsorbed 
      but did not affect the viability of any of the cells tested. Our results 
      demonstrate that New-castle disease virus caused preferential damage to lymphoma 
      cells as compared to non-cancerous normal cells.
FAU - Bar-Eli, N
AU  - Bar-Eli N
AD  - Department of Virology, Hebrew University Hadassah Medical School, Jerusalem, 
      Israel.
FAU - Giloh, H
AU  - Giloh H
FAU - Schlesinger, M
AU  - Schlesinger M
FAU - Zakay-Rones, Z
AU  - Zakay-Rones Z
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (Chromium Radioisotopes)
RN  - 0 (DNA, Neoplasm)
RN  - 0 (Phytohemagglutinins)
RN  - 0 (Pokeweed Mitogens)
RN  - 0R0008Q3JB (Chromium)
SB  - IM
MH  - Burkitt Lymphoma/metabolism/*therapy/*virology
MH  - Cell Membrane Permeability
MH  - Cell Transformation, Viral
MH  - Chromium/pharmacokinetics
MH  - Chromium Radioisotopes
MH  - Cytotoxicity, Immunologic
MH  - DNA, Neoplasm/biosynthesis
MH  - Humans
MH  - Lymphocyte Activation/drug effects
MH  - Lymphocytes/immunology/metabolism/virology
MH  - Lymphoma, B-Cell/*therapy/*virology
MH  - *Newcastle disease virus
MH  - Phytohemagglutinins/pharmacology
MH  - Pokeweed Mitogens/pharmacology
MH  - Sensitivity and Specificity
MH  - Tumor Cells, Cultured
EDAT- 1996/01/01 00:00
MHDA- 1996/01/01 00:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 1996/01/01 00:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
AID - 10.1007/BF01212880 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 1996;122(7):409-15. doi: 10.1007/BF01212880.